Sangamo Therapeutics (SGMO)
Posted: Sun Apr 19, 2020 8:42 amby investar
Bought some sgmo yesterday: 7.44$
I like the BIIB deal. I may stay in this for more than a few months.
From Fools:
Sangamo Therapeutics (NASDAQ:SGMO)one of the few companies in the gene-editing sector, often gets overshadowed by its larger competitors. Compared to stocks like CRISPR Therapeutics, which is significantly larger in market cap, Sangamo seems like a smaller player in this relatively young market. However, this healthcare stock has plenty of tailwinds many of its competitors don't enjoy.
For one, Sangamo has one of the most diverse pool of drug candidates in the entire gene-editing sector. The company has 16 separate projects ongoing at the moment, with 11 in preclinical development and five in early stage clinical testing. This is much more than CRISPR's nine drug candidates, with only three having begun early stage testing. Right now, some of Sangamo's most anticipated candidates are its transfusion-dependent beta thalassemia drug ST-400, a sickle cell disease treatment called BIVV003, and a hemophilia A drug called SB-525.
Given the uncertain nature of developing new drugs, especially in the cutting-edge field of gene-editing, there's always a big chance that something can go wrong, like a candidate flopping. As such, having a diverse portfolio means there's a bigger chance of hitting at least one clinical home run, which is all a small biotech stock like Sangamo needs to become a major success.
Sangamo is also remarkably well-funded, with around $385 million worth of cash or cash equivalents on its balance sheet. For 2019, the company reported a net loss of $95.2 million. If expenses stay relatively the same, that would mean Sangamo has just under four years' worth of cash to keep itself afloat, more than enough time for a candidate to enter late-stage trials.
The gene-editing company also has a number of major partnerships with big names in the pharmaceutical industry, including Biogen, Pfizer, and Sanofi. These deals can help provide additional capital as well as help manufacture and commercialize a potential candidate once it reaches late-stage trials.
Bought some sgmo yesterday: 7.44$
I like the BIIB deal. I may stay in this for more than a few months.
From Fools:
Sangamo Therapeutics (NASDAQ:SGMO)one of the few companies in the gene-editing sector, often gets overshadowed by its larger competitors. Compared to stocks like CRISPR Therapeutics, which is significantly larger in market cap, Sangamo seems like a smaller player in this relatively young market. However, this healthcare stock has plenty of tailwinds many of its competitors don't enjoy.
For one, Sangamo has one of the most diverse pool of drug candidates in the entire gene-editing sector. The company has 16 separate projects ongoing at the moment, with 11 in preclinical development and five in early stage clinical testing. This is much more than CRISPR's nine drug candidates, with only three having begun early stage testing. Right now, some of Sangamo's most anticipated candidates are its transfusion-dependent beta thalassemia drug ST-400, a sickle cell disease treatment called BIVV003, and a hemophilia A drug called SB-525.
Given the uncertain nature of developing new drugs, especially in the cutting-edge field of gene-editing, there's always a big chance that something can go wrong, like a candidate flopping. As such, having a diverse portfolio means there's a bigger chance of hitting at least one clinical home run, which is all a small biotech stock like Sangamo needs to become a major success.
Sangamo is also remarkably well-funded, with around $385 million worth of cash or cash equivalents on its balance sheet. For 2019, the company reported a net loss of $95.2 million. If expenses stay relatively the same, that would mean Sangamo has just under four years' worth of cash to keep itself afloat, more than enough time for a candidate to enter late-stage trials.
The gene-editing company also has a number of major partnerships with big names in the pharmaceutical industry, including Biogen, Pfizer, and Sanofi. These deals can help provide additional capital as well as help manufacture and commercialize a potential candidate once it reaches late-stage trials.